| 1.4 -0.14 (-9.09%) | 03-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.04 | 1-year : | 2.3 |
| Resists | First : | 1.75 | Second : | 1.97 |
| Pivot price | 1.56 |
|||
| Supports | First : | 1.39 | Second : | 1.16 |
| MAs | MA(5) : | 1.51 |
MA(20) : | 1.54 |
| MA(100) : | 1.4  |
MA(250) : | 1.37 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.2 |
D(3) : | 39.9 |
| RSI | RSI(14): 40.3 |
|||
| 52-week | High : | 2 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GERN ] has closed below the lower bollinger band by 10.1%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.54 - 1.55 | 1.55 - 1.56 |
| Low: | 1.38 - 1.39 | 1.39 - 1.4 |
| Close: | 1.39 - 1.4 | 1.4 - 1.41 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Sat, 28 Mar 2026
Assessing Geron (GERN) Valuation After Recent Share Price Weakness - simplywall.st
Fri, 27 Mar 2026
Geron Adds Biopharma Veterans As RYTELO Commercialization And Valuation Scrutinized - simplywall.st
Fri, 27 Mar 2026
GERN Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (NASDAQ:GERN) - chartmill.com
Thu, 26 Mar 2026
Vanguard (NASDAQ: GERN) discloses 0 share ownership after realignment - Stock Titan
Thu, 26 Mar 2026
Geron (NASDAQ: GERN) director granted 270,000 stock options at $1.57 strike - Stock Titan
Thu, 26 Mar 2026
Geron (GERN) grants director 270,000 stock options at $1.57 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 638 (M) |
| Shares Float | 511 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 78.1 (%) |
| Shares Short | 65,030 (K) |
| Shares Short P.Month | 70,450 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -45.5 % |
| Operating Margin | -17.8 % |
| Return on Assets (ttm) | -5.6 % |
| Return on Equity (ttm) | -33 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -10.77 |
| PEG Ratio | 0 |
| Price to Book value | 4 |
| Price to Sales | 4.86 |
| Price to Cash Flow | -8.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|